Grantham W. Hogeland, PharmD
Pharmacometrician
Dr. Hogeland has over 12 years of experience in Clinical Pharmacology and Pharmacometrics with a broad background in PK/PD data analysis, modeling and simulation. Dr. Hogeland has extensive experience in planning, executing, and analyzing nonclinical and clinical pharmacology studies across numerous therapeutic areas from nonclinical IND enabling studies through Phase 1 to late stage studies leading to market registration (small molecule compounds and biologics).
Dr. Hogeland has held Pharmacokineticist, Clinical Pharmacology, and Pharmacometrician positions at large and small CROs and in the biopharmaceutical industry. In these positions, he performed modeling and simulation for pharmaceutical compounds in pre-clinical, Phase 1, Phase 2 and Phase 3 of development. He has authored, reviewed, and contributed to a large number of PK(/PD) study reports, clinical study reports, clinical protocols, analysis plans, meeting briefing packets, investigator brochures, and IND annual reports. Provided scientific support for the design, analysis, reporting, and presentation of sophisticated PK/PD modeling and simulation initiatives, including population PK/PD analyses for both Phase 1 and late phase clinical trials. While in these positions he led and supported clinical pharmacology development paths and strategies, and provided clinical pharmacology/PKPD data in support of regulatory documents, agency interactions, and business development efforts.
Dr. Hogeland received a BA in Chemistry at Nebraska Wesleyan University and a PharmD from the University of Nebraska Medical Center (UNMC) – College of Pharmacy. Following graduation, he went on to complete a Pharmacy Practice Residency at the University of Iowa Hospitals and Clinics and then completed a 2-year Clinical Pharmacokinetics/Pharmacodynamics Post-Doctoral Fellowship in the Division of Pharmacotherapy and Experimental Therapeutics at the University of North Carolina at Chapel Hill. He lives in Denver, Colorado with his family.
Justus Bingham
PharmacometriciaN
Justus Bingham has 14 years of experience in the pharmaceutical industry, specifically in clinical pharmacology and pharmacokinetics and is an expert in pharmacometrics modeling and simulation. At CV Therapeutics he managed all PK/PD for the company’s pipeline across all phases of development. Mr. Bingham has a broad range of experience in both small and large molecule pharmaceutical research and development. He has held positions at Eli Lilly, CV Therapeutics and Gilead. Eight years ago Mr. Bingham transitioned to consulting and long term contracting focusing on leveraging quantitative modeling and simulation to speed up pharmaceutical development. Of significant note, Mr. Bingham has created new methodologies in statistical bootstrapping that are quicker and more accurate than standard techniques allowing them to be deployed more widely when processing time is a bottleneck to use. Mr. Bingham has significant experience as a consultant, having been the Senior Expert Consultant for modeling and simulation at Genentech, and M&S Expert Consultant for PK/PD at Certara. As an independent consultant he has provided his expertise to many companies such as Pfizer, Eli Lilly, Rosa, Navitas, Vitaeris, Gilead, STC Biologics, BASF, Dexport, Kineta Inc., University of Illinois at Champaign-Urbana super computing center and Deloitte Consulting. He has provided pharmacokinetic/pharmacodynamic, clinical pharmacology, study design, modeling and simulation, regulatory, statistics, and financial modeling assistance to clients.
Mr. Bingham’s work focuses on advancing the processes of modeling and simulation toward broader use within the research and development pipeline; in particular, with an emphasis on quantitative development. He lives in the San Francisco Bay area with his family and 3 overgrown and overfed dogs.